Literature DB >> 27109124

Right Parasternal Lead Placement Increases Eligibility for Subcutaneous Implantable Cardioverter Defibrillator Therapy in Adults With Congenital Heart Disease.

Hideo Okamura1, Christopher J McLeod, Christopher V DeSimone, Tracy L Webster, Crystal R Bonnichsen, Martha Grogan, Sabrina D Phillips, Heidi M Connolly, Naser M Ammash, Carole A Warnes, Paul A Friedman.   

Abstract

BACKGROUND: The subcutaneous implantable cardioverter defibrillator (S-ICD) provides an attractive option for patients with congenital heart disease (CHD) in whom a transvenous defibrillator is contraindicated. Given the unusual cardiac anatomy and repolarization strain, the surface electrocardiogram (ECG) is frequently abnormal, potentially increasing the screen failure rate. METHODS AND 
RESULTS: We prospectively screened 100 adult CHD patients regardless of the presence of clinical indication for ICD utilizing a standard left sternal lead placement, as well as a right parasternal position. Baseline patient and 12-lead ECG characteristics were examined to assess for predictors of screen failure. Average patient age was 48±14 years, average QRS duration was 134±37 ms, and 13 patients were pacemaker dependent. Using the standard left parasternal electrode position, 21 patients failed screening. Of these 21 patients with screen failure, 9 passed screening with the use of right parasternal electrode positioning, reducing screening failure rate from 21% to 12%. QT interval and inverted T wave anywhere in V2-V6 leads were found to be independent predictors of left parasternal screening failure (P=0.01 and P=0.04, respectively).
CONCLUSIONS: Utilization of both left and right parasternal screening should be used in evaluation of CHD patients for S-ICD eligibility. ECG repolarization characteristics were also identified as novel predictors of screening failure in this group. (Circ J 2016; 80: 1328-1335).

Entities:  

Mesh:

Year:  2016        PMID: 27109124     DOI: 10.1253/circj.CJ-16-0153

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  9 in total

1.  Eligibility for subcutaneous implantable cardioverter-defibrillator in congenital heart disease.

Authors:  Linda Wang; Neeraj Javadekar; Ananya Rajagopalan; Nichole M Rogovoy; Kazi T Haq; Craig S Broberg; Larisa G Tereshchenko
Journal:  Heart Rhythm       Date:  2020-05       Impact factor: 6.343

2.  Conventional and right-sided screening for subcutaneous ICD in a population with congenital heart disease at high risk of sudden cardiac death.

Authors:  Pau Alonso; Joaquín Osca; Joaquín Rueda; Oscar Cano; Pedro Pimenta; Ana Andres; María José Sancho; Luis Martinez
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-05-15       Impact factor: 1.468

3.  Subcutaneous implantable cardioverter defibrillator eligibility according to a novel automated screening tool and agreement with the standard manual electrocardiographic morphology tool.

Authors:  Pietro Francia; Matteo Ziacchi; Paolo De Filippo; Stefano Viani; Antonio D'Onofrio; Vincenzo Russo; Carmen Adduci; Mauro Biffi; Paola Ferrari; Valter Bianchi; Ernesto Ammendola; Francesca Palano; Jessica Frisoni; Sergio Valsecchi; Mariolina Lovecchio; Maria Grazia Bongiorni
Journal:  J Interv Card Electrophysiol       Date:  2018-03-03       Impact factor: 1.900

4.  Right versus left parasternal electrode position in the entirely subcutaneous ICD.

Authors:  Markus Bettin; Dirk Dechering; Gerrit Frommeyer; Robert Larbig; Andreas Löher; Florian Reinke; Julia Köbe; Lars Eckardt
Journal:  Clin Res Cardiol       Date:  2017-12-28       Impact factor: 5.460

Review 5.  Narrative review of: risk stratification and implantable cardioverter-defibrillator therapy in adults with congenital heart disease.

Authors:  Julia Köbe; Kevin Willy; Lars Eckardt; Helmut Baumgartner; Kristina Wasmer
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

6.  Impact of SMART Pass filter in patients with ajmaline-induced Brugada syndrome and subcutaneous implantable cardioverter-defibrillator eligibility failure: results from a prospective multicentre study.

Authors:  Giulio Conte; Fabio Cattaneo; Carlo de Asmundis; Paola Berne; Alessandro Vicentini; Mehdi Namdar; Antonio Scalone; Catherine Klersy; Maria Luce Caputo; Andrea Demarchi; Tardu Özkartal; Francesca Salghetti; Gavino Casu; Ilaria Passarelli; Stefano Mameli; Dipen Shah; Haran Burri; Gaetano De Ferrari; Pedro Brugada; Angelo Auricchio
Journal:  Europace       Date:  2022-05-03       Impact factor: 5.486

7.  Entirely subcutaneous defibrillator and complex congenital heart disease: Data on long-term clinical follow-up.

Authors:  Paolo Ferrero; Hussam Ali; Palash Barman; Sara Foresti; Pierpaolo Lupo; Emilia D'Elia; Riccardo Cappato; Alan Graham Stuart
Journal:  World J Cardiol       Date:  2017-06-26

8.  Eligibility for subcutaneous implantable cardioverter-defibrillator in adults with congenital heart disease.

Authors:  Christos Zormpas; Ann Sophie Silber-Peest; Jörg Eiringhaus; Henrike A K Hillmann; Stephan Hohmann; Johanna Müller-Leisse; Mechthild Westhoff-Bleck; Christian Veltmann; David Duncker
Journal:  ESC Heart Fail       Date:  2021-02-03

9.  Initial experience with the subcutaneous implantable cardioverter-defibrillator in a single Japanese center.

Authors:  Nobuhiro Nishii; Motomi Tachibana; Yoshimasa Morimoto; Satoshi Kawada; Akihito Miyoshi; Hiroyasu Sugiyama; Koji Nakagawa; Atsuyuki Watanabe; Kazufumi Nakamura; Hiroshi Morita; Hiroshi Ito
Journal:  J Arrhythm       Date:  2017-03-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.